BioSpace News Archive

Recro Pharma, Inc., a contract development and manufacturing organization dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid dose drug products, announced the expansion of its team through the addition of new employees to support business development, technical operations and certain strategic initiatives.

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus infection, as well as therapies to treat coronaviruses, announced it has received authorization from the U.S. Food and Drug Administration to proceed with its Investigational New Drug application for AB-729 in a Phase 2a clinical trial.

Trevena, Inc., a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system disorders, announced it has initiated a new study evaluating the physiologic impact of OLINVYK on respiratory function in elderly / obese subjects.

Leap Therapeutics, Inc. announced that Douglas E. Onsi, President and Chief Executive Officer, will present a corporate overview at the Ladenburg Thalmann 2021 Virtual Healthcare Conference on Wednesday, July 14, 2021 at 1:00 p.m. Eastern Time.

Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, announced the appointment of Adam Cutler as Chief Financial Officer.

PureTech Health plc announced a clinical trial and supply agreement with an affiliate of BeiGene, Ltd. to evaluate BeiGene’s tislelizumab, an anti-PD-1 immune checkpoint inhibitor, in combination with PureTech’s LYT-200, an investigational monoclonal antibody targeting galectin-9, for the potential treatment of difficult-to-treat solid tumor indications that are associated with poor survival rates.

Sierra Oncology, Inc., a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer, granted stock options to five new employees as approved by the Compensation Committee of the Company’s Board of Directors, under Sierra Oncology’s 2018 Equity Inducement Plan.

Augmedics, a pioneer in augmented reality surgical image guidance, announced the appointment of Rick Anderson as executive chairman of the board and Bradley Paddock as the board’s independent director.

Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced that it will participate in the Ladenburg Thalmann’s Virtual 2021 Healthcare Conference held July 13-14, 2021.

Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba, will present a company overview during the Ladenburg Thalmann Virtual Healthcare Conference